NCT03266185 (COP) is a NA clinical trial of Shorter PICT in Neoplasm Malignant, sponsored by Leiden University Medical Center.

Who is sponsoring NCT03266185?

NCT03266185 is sponsored by Leiden University Medical Center.

What drugs are being tested in NCT03266185?

Interventions in NCT03266185: Shorter PICT.

What condition does NCT03266185 study?

NCT03266185 studies Neoplasm Malignant, Breast Cancer, Ovarian Cancer.

Is NCT03266185 still recruiting?

NCT03266185 is currently completed. Last updated 1 April 2021.

Last reviewed 2021-04-01 · How we verify

NCT03266185: COP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shorter Scalp Cooling Time in Paclitaxel

Completed NA Last updated 1 April 2021

What this trial tests

NA trial testing Shorter PICT in Neoplasm Malignant in 91 participants. Completed in 28 August 2020.

Timeline

20 December 2017

Primary endpoint
28 August 2020

28 August 2020

Quick facts

Lead sponsor	Leiden University Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	91
Start date	20 December 2017
Primary completion	28 August 2020
Estimated completion	28 August 2020
Sites	1 location across Netherlands

Drugs / interventions tested

Shorter PICT

Conditions studied

Neoplasm Malignant — all drugs for Neoplasm Malignant →
Breast Cancer — all drugs for Breast Cancer →
Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Leiden University Medical Center

Who can join

18 and older, any sex, with Neoplasm Malignant or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chemotherapy-induced alopecia (CIA) is one of the most distressing side effects for patients. Scalp cooling can prevent or minimise CIA in approximately half of all patients, depending on many factors, e.g. type and dosage of chemotherapy. High rates of success are seen in patients treated with taxanes, up to 80-90%. Previous research has shown comparable results of scalp cooling in docetaxel-treated patients when shortening the post-infusion cooling time (PICT) from the initial standard of 90 minutes to 45- and 20 minutes. A shorter PICT is an advantage for both the patient, who can spend less time in the hospital, as well for the logistics at oncological departments. Paclitaxel and docetaxel are both classical taxanes, that share similar mechanisms of action and have comparable plasma terminal half-life times, therefore it seems plausible that the PICT can be shortened for paclitaxel-treated patients as well.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia - a randomized controlled trial.
Lugtenberg RT, van den Hurk CJG, Smorenburg CH, Mosch L, et al · · 2022 · cited 3× · PMID 35501515 · DOI 10.1007/s00520-022-07090-7

Verify or expand the search:

Other recruiting trials for Neoplasm Malignant

Currently open trials in the same condition.

NCT07209111 — A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) · Phase 2 · recruiting
NCT06782451 — Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity · NA · recruiting
NCT06606366 — Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplina · NA · recruiting
NCT06575127 — Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two · Phase 2 · recruiting
NCT04987359 — A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer · NA · active not recruiting

Other Leiden University Medical Center trials

Trials by the same sponsor.

NCT07312565 — Occurrence of Abdominal Aortic Aneurysms in Patients With Aneurysmal Subarachnoid Hemorrhage · not yet recruiting
NCT07090343 — Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement · Phase 3 · not yet recruiting
NCT07498738 — Making Diabetes Care Fit for Young Adults Living With Type 1 Diabetes: Observations, Reflections and Expert Opinions · NA · not yet recruiting
NCT06545292 — Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients · NA · recruiting
NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03266185 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Leiden University Medical Center
Last refreshed: 1 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03266185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing